{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:19Z","timestamp":1707524599123},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,12]]},"DOI":"10.7759\/cureus.26793","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:49:55Z","timestamp":1657673395000},"source":"Crossref","is-referenced-by-count":0,"title":["Saved by the Scan: A Case of Early Detection of Sarcomatoid Mesothelioma"],"prefix":"10.7759","author":[{"given":"Hasan","family":"Choudhury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Budde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayab","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Comfort","family":"Adewunmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Pathology of malignant pleural mesothelioma","author":"Litzky LA","year":"2020","unstructured":"Litzky LA. Pathology of malignant pleural mesothelioma. UpToDate. Nicholson A, Jett J, Lilnbaum R (ed): UpToDate, Waltham; 2020."},{"key":"ref2","unstructured":"Mesothelioma recent trends in SEER age-adjusted incidence rates, 2000-2019. (2019). Accessed. July 12, 2022: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html."},{"key":"ref3","article-title":"Peritoneal mesothelioma: a review","volume":"9","author":"Bridda A","year":"2007","unstructured":"Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007, 9:32.","journal-title":"MedGenMed"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.10.09","article-title":"Clinical diagnosis of malignant pleural mesothelioma","volume":"10","author":"Bianco A","year":"2018","unstructured":"Bianco A, Valente T, De Rimini ML, Sica G, Fiorelli A. Clinical diagnosis of malignant pleural mesothelioma. J Thorac Dis. 2018, 10:S253-61. 10.21037\/jtd.2017.10.09","journal-title":"J Thorac Dis"},{"key":"ref5","article-title":"Latent period for malignant mesothelioma of occupational origin","volume":"34(7)","author":"Lanphear BP","year":"1992","unstructured":"Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992, 34(7):718-721.","journal-title":"J Occup Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle DR","year":"2011","unstructured":"Aberle DR, Adams AM, Berg CD, et al.. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011, 365:395-409. 10.1056\/NEJMoa1102873","journal-title":"N Engl J Med"},{"key":"ref7","unstructured":"Malignant pleural mesothelioma. (2021). Accessed. November 26, 2021: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1442."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al.. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021, 397:375-386. 10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli GL","year":"2019","unstructured":"Ceresoli GL, Aerts JG, Dziadziuszko R, et al.. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet. 2019, 20:1702-1709. 10.1016\/S1470-2045(19)30532-7","journal-title":"Lancet"},{"key":"ref10","unstructured":"Ph 2\/3 study in subjects with MPM to assess ADI-PEG 20 with pemetrexed and cisplatin (ATOMIC). (2022). Accessed. July 10, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02709512."},{"key":"ref11","unstructured":"Survival rates for mesothelioma. (2022). Accessed. June 19, 2022: https:\/\/www.cancer.org\/cancer\/malignant-mesothelioma\/detection-diagnosis-staging\/survival-statistics.html."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/103071-saved-by-the-scan-a-case-of-early-detection-of-sarcomatoid-mesothelioma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:41Z","timestamp":1707507521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/103071-saved-by-the-scan-a-case-of-early-detection-of-sarcomatoid-mesothelioma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.26793","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,12]]}}}